Synthetic Nucleic Acid Targeting KIF26B for Ectopic Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for pathologic calcification or bone formation, particularly in cases of intra-articular ectopic calcification and heterotopic ossification, which often result from injury or surgery, and are recalcitrant to therapy.
Innovation Solution
Administration of a therapeutically effective amount of a synthetic nucleic acid targeting KIF26B, such as small hairpin RNA (shRNA), to inhibit KIF26B expression, thereby reducing osteogenesis and promoting chondrogenesis, and inhibiting the development of ectopic calcification and heterotopic ossification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for pathologic calcification, then existing therapy options are limited, but treatment effectiveness is insufficient
Solution Approach 1:
The patent introduces KIF26B as a molecular intermediary target that mediates the pathological process of ectopic calcification. By targeting this specific protein with synthetic nucleic acids, the invention creates a new therapeutic pathway that is both effective and adaptable to different calcification conditions
Solution Approach 2:
The invention changes the therapeutic parameter from general symptomatic treatment to specific molecular target inhibition. By altering the treatment approach to target KIF26B expression levels, the patent achieves both improved effectiveness and versatility across different pathologic calcification scenarios
2Object-affected harmful factors
If KIF26B expression is inhibited, then osteogenesis is reduced and ectopic calcification is prevented, but cell proliferation and viability are decreased
Solution Approach 1:
The patent applies local quality by targeting KIF26B inhibition specifically in affected tissues showing signs of pathologic calcification or heterotopic ossification, rather than systemically inhibiting all osteogenic activity. This localized approach prevents ectopic bone formation while preserving normal cellular functions in healthy tissues
Solution Approach 2:
The invention uses partial action by employing synthetic nucleic acids that achieve sufficient KIF26B inhibition to prevent calcification without completely eliminating osteogenic potential. The treatment is calibrated to provide the minimum necessary inhibition to prevent pathology while maintaining normal cellular proliferation and viability
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of methods for treating pathologic calcification or bone formation and methods of inhibiting KIF26B that include administering a therapeutically effective amount of a synthetic nucleic acid against KIF26B. Compositions comprising a small hairpin RNA (shRNA) against KIF26B are also provided.